Maribavir is not recommended to be co-administered with valganciclovir/ganciclovir.
- TRADE NAME: Livtencity (Takeda)
- INDICATIONS: Treatment of cytomegalovirus disease/infection.
- HALF-LIFE: 4 hours
- FDA APPROVAL DATE: 11/23/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Cyclosporine, CYP3A4 inducers, Digoxin, Everolimus, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rosuvastatin, Sirolimus, St John's Wort, Tacrolimus - PREGNANCY: No adequate human data currently available to establish if there is a risk to pregnancy outcomes.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
